Method for preventing bronchopneumonia in piglets

FIELD: agriculture, veterinary science.

SUBSTANCE: during the 1st d after forming raising groups one should once inject intramuscularly a solution of "Complex A" preparation at the dosage of 0.30-0.32 mg/kg body weight for 45-60-d-aged piglets and simultaneously with fodder one should introduce "Lactobifadol" preparation at the quantity of 0.50-0.52 g/kg body weight during the first 1-5 d. The present innovation enables to activate immune system, increase total protein and hemoglobin in blood that in its turn, prevents bronchopneumonia and remove stress in piglets after forming special raising groups.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

 

The invention relates to agricultural production, in particular for veterinary medicine, and can be used for the prevention of pneumonia in animals.

A significant role in the etiology and pathogenesis of bronchopneumonia in animals played by viruses, bacteria, Mycoplasma, fungi and their Association. Microorganisms often cause disease due to lowered body resistance. So along with causal means for the prevention and treatment bronchopneumonia in piglets need to use drugs that increase the level of General resistance of the organism.

Known way to prevent pneumonia in pigs with the use of antibacterial drugs (Shahi A.G., Antipov, VA, Sukhov N.M. and other Drugs tylosin when bronchopneumonia pigs, J. Pig, 1982, No. 1, p.32).

The disadvantage of this method is that the use of antimicrobial drugs known side effects: along with pathogenic microorganisms, killing and useful, normal flora of the body; the microorganisms can quickly develop resistance to antibiotics (especially enterobacteria, stafilo-streptococci, Pseudomonas aeruginosa); the suppression of the resistance of the organism.

Known way to prevent pneumonia in pigs, including the use of means of promoting the x and nonspecific resistance of the organism of animals (tincture of a ginseng, Eleutherococcus, gamma-globulins, nonspecific polyglobulia, vitamins (and others) (Dusuk RV Therapeutic measures and medicines with pneumonia of pigs. Bull. VIEW., M., 1975, VIP, p.64-65).

The disadvantage of this method means that increase the body's resistance, is that newborn piglets up to 60% perebolevayet dyspepsia (diarrhea). As a result, they dysbacteriosis, and they often remain carriers of conditionally pathogenic microflora. Flora habitats of the body are interrelated. Recovered pigs often in the future ill with bronchopneumonia. Use tools that increase resistance of the body in times of stress (translation in the rearing and others), does not eliminate the dysbacteriosis of the gastrointestinal tract, and these piglets remain "at risk", i.e. the next time the stress there is a danger of disease bronchopneumonia.

The task of the invention is to effectively prevent pneumonia and improve the productivity of piglets and stress after forming groups of growers. Translation piglets at Piglet is, as a rule, at the age of 45-60 days.

In the proposed method, unlike the prototype, the first day after the formation of groups of growers (45-60 days of age) pigs intramuscularly one is care the solution is "Complex And" in a dose of 0.30-0,32 mg/kg body weight and at the same time together with food in the first 5 days to introduce the drug "Lactometer" in the amount of 0.5-0.52 g/kg of body weight.

Example: the Experiments were carried out in the Plant of the Elite district of the district of Krasnoyarsk region. As a drug to increase the resistance of the organism of pigs was applied immunomodulator nucleic nature "Complex And" a preparation on the basis of dsRNA WESTIN obtained in NICHIBAN GNCB "Vector", Novosibirsk. For prophylaxis of a dysbacteriosis of the intestine in piglets used probiotic "Lactometer" (trubia form) (producer - 000 Biotech firm "Component", Buguruslan, Orenburg region).

Test the preventive efficacy of drug combinations with pneumonia held at 150 pigs 2 months of age after forming groups of growers. Animals were divided into 3 groups. The piglets of the first (n=50) and second (n=50) groups on the first day after weaning and forming groups of growers were injected intramuscularly once the solution is "Complex And" in a dose of 0.30-0,32 mg/kg of body weight. Animals of the first group (n=50), in addition, food is injected with a drug "Lactometer" (grubuna form) during the first 5 days after the formation of groups of growers at a dose of 0.50 to 0.52 g/kg of body weight. Piglets of the third group (n=50) served as a control.

The animals were clinically observed for 30 days, take into account the incidence, growth rate, mortality.

Before treatments, cures and 25 days after administration of the immunomodulator, 5 piglets from each group took blood for carrying out morphological and immunobiochemical research and nasal mucus for bacteriological studies. Results from clinical trials are presented in the table.

Table

The results of applying the immunomodulator nucleic nature "Complex And" in combination with a probiotic with a preventive purpose in bronchopneumonia pigs
No. n/aIndicatorsThe group of animals treatedControl
pdrug "Complex And" in combination with "Laccopetalum"drug "Complex And"
1Number of animals in the experience, goal505050
2Involuntarily killed a goal./%--1(2,0%)
3Died a goal./%1(2,0%)1(2,0%)2(4,0%)
4Ill with bronchopneumonia, a goal./%4(8,0%)4(8,0%)10(20,0%)
5Average daily weight gain, g107,06,3 59,2

The table shows that the introduction of once immunomodulator "Complex And" in the amount of 0.30-0,32 mg/kg body weight in combination with probiotic "Lactometer" within the first 5 days at a dose of 0.50 to 0.52 g/kg of body weight after the formation of rearing groups (1st group), and the use of immunomodulator "Complex And" in a dose of 0.30-0,32 mg/kg body weight (group 2 piglets) prevents the incidence of bronchopneumonia in 90.0% of cases. In the group of piglets treated with the drug "Complex And" in combination with probiotic "Lactometer", ill with bronchopneumonia 4 (8,0%) heads, forced killed there. Similar results were obtained in the 2-nd group of piglets treated with the drug "Complex". In the control group became infected with bronchopneumonia 10 (20,0%), forced killed 1 (2,0%)died 2 (4.0%) of animals. Therefore, the incidence of pigs decreased by 12%, were killed in 2 times less than in control.

Average daily weight gain of piglets treated with the drug "Complex And" in combination with probiotic "Lactometer was higher (107,0 g) compared with piglets other groups; treated with immunomodulator (86,3 g), and animals that are not treatable by drugs (59,2 g).

The laboratory investigations 3 days after administration of the immunomodulator showed a slight increase in blood e is trozitos (experimental groups 5,95± 0.35 and 5,70±, and 0.40 1012/l) in comparison with control (4,94±0,22 1012/l); hemoglobin (respectively 107,06±1.70 g/l; 107,80±2,10 g/l and 98.67±2,77 g/l); total protein (respectively 7,07±0.12 g%; 7,11±0.17 g% 6,54±0.31 g%); gamma-globulin (respectively 33,14±1,65%; 35,12±3,83% 24,82±2,37%); also the increase in the bactericidal activity of blood serum (respectively 87,09±3,67%; 86,71±5,39% and 75,95±3,97); phagocytic activity of leukocytes (respectively FAL 72,60±3,12%; 75,20±3,57% 64,40±4,46; FC (phagocytic number) 4,70±0,31; 4,78±0,27 and 3.70±0,35). In the study of blood through 25 days after administration of the immunomodulator significant difference indices (erythrocyte sedimentation rate, hemoglobin, erythrocytes, leukocytes, total protein, protein fractions, and bactericidal activity of blood serum, phagocytic activity of leukocytes, leukocyte formula) is not marked.

Bacteriological examination of nasal mucus in 5 pigs from each group after 3 and 25 days after the drug "Complex A", also drug "Complex And" in combination with laccopetalum there was no significant difference in the composition of the microflora of the mucous membranes of the nasal cavities of piglets from the experimental groups in comparison with control. In the study 25 days after administration of the immunomodulator in combination with laccopetalum identified in the osovaya mucus animals fewer virulent for white mice crops (2) compared with piglets, treated with immunomodulator (3) control (6 crops).

Bacteriological examination of the lungs, bronchial and mediastinal lymph nodes, parenchymatous organs from forced murdered ill with bronchopneumonia pig (30 day experience) of light selected pathogenic culture beta-hemolytic streptococci in Association with E. coli. From other bodies of the microorganisms were isolated.

Thus, the combination of drugs that increase the body's resistance "Complex a" and probiotic "Lactometer", effective for prophylactic use in pneumonia of pigs, as well as obtaining weight gain and relieve stress after forming groups of growers.

The combined use of drugs that increase the body's resistance, and probiotic (normal intestinal flora) gives the opportunity not only to enhance the body's resistance to adverse effects of stress factors, but also normalizes the microbiocenosis of the mucous membranes of the intestines (which also leads to a decrease in the incidence of gastro-intestinal diseases). This leads to risk reduction in the incidence of animals with bronchopneumonia, and increase the growth rate of animals.

The positive effect of the combined use of the drugs is that in times of stress they increases the ut resistance of animals, at the same time normalize the microflora of the gastrointestinal tract. Profilaktorua gastrointestinal illness and as a consequence preventing the formation of permanent policella of pathogenic microorganisms in natural habitats of the body (the microbiocenosis of biotopes of the body are interrelated), we hereby warn the incidence of bronchopneumonia and helps to relieve stress and increase the gain of the piglets.

The method is easily implemented in agricultural production.

The way to prevent pneumonia in piglets, including the use of drugs, characterized in that on the first day after the formation of groups of growers in 45-60 days of age pigs intramuscularly once the solution is "Complex And" in a dose of 0.30-0,32 mg/kg body weight and at the same time together with food in the first 1-5 days to introduce the drug "Lactometer" in the amount of 0.50 to 0.52 g/kg of body weight.



 

Same patents:

FIELD: medicine, ophthalmology.

SUBSTANCE: as an immunomodulating remedy one should introduce tamerite per 0.5 ml subconjunctivally and per 1.5 ml i/m daily for 5 d. The method provides normalization of immunity values due to additional local complex manifestation of immunomodulating, antiphlogistic, antioxidant and regenerating effects of tamerite.

EFFECT: higher efficiency of complex therapy.

2 ex

FIELD: food industry.

SUBSTANCE: invention relates to food additives that can be used to prevent immunodeficiency conditions. Immunomodulator is prepared via homogenization of lymphatic nodes in sodium chloride solution, autolysis, centrifugation, heating of supernatant to 80°C, cooling, removal of precipitate, and drying of supernatant by cooling it and placing it into atmospheric sublimation installation followed by subsequent post-drying using IR drying technique.

EFFECT: simplified immunomodulator preparation process and preserved biological and food values of finished product without creation of special temperature regime.

5 tbl, 2 ex

FIELD: applied immunology.

SUBSTANCE: composition contains, wt parts: borax decahydrate1-25, sodium thiosulfate pentahydrate 10-5-10-4, potassium carbonate 30-150, refined sugar 30-200, and water 100-200 per 100 wt parts of sodium metasilicate pentahydrate. In addition to its capability of improving resistance to diseases, body weight increase, productivity of agricultural plants, quality of crop, and ripening term (harvest time), composition according to invention possesses nonspecific immunostimulating activity, including production of antibodies and enhancement of immunity through activation of immunocytes thereby maximally strengthening vaccination effect regarding diseases caused by malignant neoplasm viruses.

EFFECT: increased assortment of immunostimulating agents.

10 cl, 11 dwg, 12 ex

FIELD: medicine, immunology, veterinary science, pharmacy.

SUBSTANCE: invention concerns a medicinal agent modulating the immune response of body. Agent is made as a tablet covered by envelope. The table core comprises thymus preparation, sodium nucleate, potato starch and the accessory substances taken in the definite ratio of components. As the thymus preparation immunomodulating agent can comprise tactivine or thymaline, or thymogen. The core is covered by envelope comprising acetylphthalylcellulose, castor oil, vaseline oil, titanium dioxide, tropeolin "O" taken in the definite ratio of components. Invention expands assortment of immunomodulating agent by the development of immunomodulating agent that acts on T- and B-lymphocytes simultaneously and on macrophage link of immune system that is suitable in using by children and other patient groups for a long time wherein injection method of administration is not desirable. The immunomodulating agent "Ribotab" elicits high effectiveness providing correction of immunity by tableting agent "Ribotab" after its using in a single dose.

EFFECT: improved and valuable properties of agent.

2 cl, 2 tbl, 5 ex

FIELD: medicine, pediatrics, pulmonology.

SUBSTANCE: in blood serum under testing one should detect the level of specific IgE-AB to S. pneumoniae antigen and at its value being above 0 kU/l it is necessary to perform single vaccination with "Pneumo 23" preparation at the dosage of 0.5 ml intramuscularly regardless of the period of exacerbation at the background of basic therapy. The present innovation enables to increase immunity that in its turn increases efficiency of pharmacotherapy at bronchial asthma and decreases sickness rate at ARVI.

EFFECT: higher efficiency of prophylaxis.

2 ex

Immunomodulator // 2252757

FIELD: immunology.

SUBSTANCE: invention relates to application of 2-Br-phenoxyacetic acid tris-(2-oxiethyl)ammonium salt with antioxidant activity as immunomodulator. Claimed compound gas stimulates action on mieloactivity and original humoral response, which was estimated on the base of amount of lgM-antibody forming cells, as well as depressive action on cell immune response and cell proliferation of spleen. Compound of present invention with immunological properties is useful in production of pharmaceuticals for treatment of various immune pathological conditions.

EFFECT: new application of known antioxidant as immunomodulator.

4 ex, 4 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested methods and compositions provide transfer of biologically active compound, antigen predominantly, in animal body. Efficient quantity of biologically active compound should be put into microcapsules made of biocompatible material the size of which do not exceed 10 mcm, then one should introduce efficient quantity of these microcapsules, perorally, preferably, for animals under immunization. As material for microcapsules one usually applies a biologically active polymer or copolymer being of capacity to pass through gastro-intestinal tract or being localized at mucosal surface not being affected by biodegradation. This provides the transfer of biologically active compound onto Peyer's patches or other mucosa-associated lymphatic tissues, that provides inducing systemic immunity and activization of mucosal immunity system.

EFFECT: higher efficiency.

22 cl, 12 ex, 19 tbl

FIELD: medicine.

SUBSTANCE: method involves taking lavage fluid samples from injured bronchi in preoperative period in making fiber-optic bronchoscopy examination. Microflora colonizing bronchial mucous membrane and its sensitivity to antibiotics is determined. Therapeutic dose of appropriate antibiotic and therapeutic dose of immunomodulator agent like leykinferon is introduced in endolymphatic way 40-60 min before operation. Smears are taken from outlying bronchi in doing operation. Sputum or fluid in retained pleural cavity are taken in 1-2 days after the operation. Prophylaxis effectiveness is determined on basis of bacteriological study data. Therapeutic dose of antibiotics and leykinferon are introduced in 6-8 and 20-24 h after the operation in endolymphatic way. The preparations are introduced at the same doses in endolymphatic way making pauses depending on selected antibiotic elimination half-time once or twice a day until the drains are removed mostly during 48-72 h after operation.

EFFECT: enhanced effectiveness of antibacterial protection; high reliability of antibiotic prophylaxis.

FIELD: organic chemistry, medicine, immunology.

SUBSTANCE: invention proposes applying 2,4-dichlorophenoxyacetic acid tris-(2-oxyethyl)-ammonium salt as an immunomodulating agent. The newly found properties provide the development on its base medicinal agents for treatment of inflammatory, autoimmune and lymphoproliferative diseases.

EFFECT: valuable medicinal properties of agent, expanded assortment of agents of indicated designation.

4 tbl, 4 ex

FIELD: medicine, immunology, peptides.

SUBSTANCE: invention relates to a new composition of biologically active substances. Invention proposes the composition comprising of peptides of the formula: Arg-Gly-Asp and H-Tyr-X-Y-Glu-OH wherein X means Gln and/or Glu; Y means Cys(acm) and/or Cys that elicits ability to inhibit the proliferative response for phytohemagglutinin, to induce the suppressive activity of mononuclear cells and ability of peptides to induce secretion of immunosuppressive cytokines of grouth-transforming factor-β1 and interleukin-10 (IL-10). The composition can be prepared by a simple procedure.

EFFECT: valuable biological properties of composition.

3 cl, 16 tbl, 9 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention concerns to applying RARγ agonist for preparing a medicinal agent comprising one or some such agonists and designated for treatment of emphysema wherein RARγ agonist is taken among compounds of the formula (I):

wherein R1 means residue of the formula:

or , or , or ; R2 means (C2-C8)-alkanoyl, (C2-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl or group -OCH2R3 wherein R3 means hydrogen atom, (C1-C6)-alkyl, (C2-C6)-alkenyl or (C2-C6)-alkynyl; each among R4-R9 means independently of one another hydrogen atom or (C1-C6)-alkyl; or R8 and R9 mean in common (CRaRb)n wherein Ra and Rb mean independently of one another hydrogen atom or (C1-C6)-alkyl; n = 1, 2 or 3; R4-R7 have above given values; R10 means carboxyl, (C1-C6)-alkoxycarbonyl or mono- or di-(C1-C6)-alkylcarbamoyl; and their pharmaceutically acceptable salts; or among compounds of the formula (VI):

wherein R1 means C(O)R6 or CH2OH (wherein R6 means hydroxy-group or (C1-C6)-alkoxy-group); R2 means hydrogen atom, (C1-C15)-alkyl, (C1-C6)-alkoxy-group or cycloaliphatic group; R3 means hydrogen atom, hydroxy-group, (C1-C6)-alkyl, dihydroxy-(C1-C6)-alkyl, (C1-C10)-alkoxy-group or cycloaliphatic group; R4 and R5 mean independently of one another hydrogen atom, hydroxy-group, (C1-C6)-alkyl, (C1-C6)-alkoxy-group; or among compound of the formula (VIII):

. Invention provides applying agonists eliciting the selective effect with respect to RARγ, for preparing a medicinal agent comprising one or some such agonists designated for emphysema treatment.

EFFECT: valuable medicinal properties of compounds.

4 cl, 5 tbl, 3 ex

FIELD: medicine, gynecology, anesthesiology.

SUBSTANCE: invention concerns to a method for carrying out the anesthesiology assistance for woman in childbirth with accompanying bronchial asthma. Method involves administration of atropine, dimedrol, analgin and clophelin. Method involves additional intravenous administration of transamine for 5-7 min. Transamine is administrated in doses 12-14 and 15-17 mg/kg in woman in childbirth with body mass 75 kg and above and 74 kg and less, respectively. Method provides enhancing quality and safety of anesthesia in this class of woman in childbirth.

EFFECT: improved assistance method.

7 tbl, 4 ex

FIELD: medicine, pulmonology, surgery.

SUBSTANCE: method involves the conventional complex treatment comprising using antibiotics. Method involves additional administration of serotonin adipinate in the dose 10 mg, not less, for 30 min by intravenous drop route wherein drug is dissolved in physiological solution. Method provides limitation in propagation of the suppurative-destructive process in lungs due to improving microcirculation in zone of perifocal inflammation. Invention can be used in treatment of patients with lung abscess.

EFFECT: improved treatment method.

2 tbl, 2 ex

FIELD: veterinary science.

SUBSTANCE: one should apply intrapleural novocaine-antibiotic blockade in combination with intramuscular injection of 10%-erancond-B solution at the dosage of 3.0 -3.5 mg/kg body weight for the first 4-5 d of therapy. Calves should be daily given a tincture out of coltsfoot leaves prepared at the ratio of 1 portion of grass per 10 portions of water, at 90 - 110 ml/calf thrice daily. Intake of 0.5 - 0.6 g ascorbic acid should last for 5-7 d. The method provides activation of immune systems, T-system, phagocytic and interferonogenic ones, in particular.

EFFECT: higher efficiency of therapy.

1 ex, 4 tbl

FIELD: restorative medicine, pediatrics.

SUBSTANCE: the method deals with inhalations conducted with Hanks' solution at dispersity of particles being 0.8-2 mcm, expenditure of preparation being 1 ml/3.5 min Inhalation time corresponds to 8-10 min, daily. One should perform about 10-12 procedures per a course at the background of complex therapy including the adequate mode of motor activity, curative physical culture, carbonic acid baths. The method enables to improve sputum withdrawal and, correspondingly, bronchial permeability and the values for the function of external respiration.

EFFECT: more prolonged remission.

1 ex, 2 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of adamantane of the general formula:

wherein m = 1 or 2; each R1 represents independently hydrogen atom; A represents C(O)NH or NHC(O); Ar represents the group:

or

wherein X represents a bond, oxygen atom or group CO, (CH2)1-6, CH=, O(CH2)1-6, O(CH2)2-6O, O(CH2)2-3O(CH2)1-3, CR'(OH), NR5, (CH2)1-6NR5, CONR5, S(O)n, S(O)nCH2, CH2S(O)n wherein n = 0, 1 or 2; R' represents hydrogen atom; one of R2 and R3 represents halogen atom, nitro-group, (C1-C6)-alkyl; and another is taken among R2 and R3 and represents hydrogen or halogen atom; either R4 represents 3-9-membered saturated or unsaturated aliphatic heterocyclic ring system comprising one or two nitrogen atoms and oxygen atom optionally being heterocyclic ring system is substituted optionally with one or more substitutes taken independently among hydroxyl atoms, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, -NR6R7, -(CH2)rNR6R7; or R4 represents 3-8-membered saturated carbocyclic ring system substituted with one or more substitutes taken independently among -NR6R7, -(CH2)NR6R7 wherein r = 1; R5 represents hydrogen atom; R6 and R7 each represents independently hydrogen atom or (C1-C6)-alkyl, or (C2-C6)-hydroxyalkyl group eliciting antagonistic effect with respect to R2X7-receptors. Also, invention describes a method for their preparing, pharmaceutical composition comprising thereof, a method for preparing the pharmaceutical composition and their applying in therapy for treatment of rheumatic arthritis and obstructive diseases of respiratory ways.

EFFECT: improved method for preparing and treatment, valuable medicinal properties of compounds.

13 cl, 88 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to new acid-additive nitrate salts of compounds taken among salbutamol, cetirizine, loratidine, terfenadine, emedastine, ketotifen, nedocromil, ambroxol, dextrometorphan, dextrorphan, isoniazide, erythromycin and pyrazinamide. Indicated salts can be used for treatment of pathology of respiratory system and elicit an anti-allergic, anti-asthmatic effect and can be used in ophthalmology also. Indicated salts have less adverse effect on cardiovascular and/or gastroenteric systems as compared with their non-salt analogues. Also, invention proposes pharmaceutical compositions for preparing medicinal agents for treatment of pathology of respiratory system and comprising above indicated salts or nitrate salts of metronidazol or aciclovir.

EFFECT: improved and valuable properties of compounds.

6 cl, 5 tbl, 19 ex

FIELD: pharmaceutical industry, in particular homoeopathic drug for treatment of acute respiratory virus infections.

SUBSTANCE: claimed drug includes Aconitum C3, Baptisia trinctoria C3, China C3, Allium cepa, Atropa belladonna, Bryonia alba D3, and Mercurius solubilis C6 in equal ratios. Homoeopathic drug may be made in form of granules or drops. Drug of present invention has potent antipyretic, anti-inflammatory and deintoxication action.

EFFECT: homoeopathic drug with good endurability without side effects.

2 cl, 4 tbl

FIELD: medicine, in particular homoeopathic ointment for treatment of hemorrhoids, dermatitis and rhinitis.

SUBSTANCE: claimed ointment includes Calendula D 1, Hamamelis D 1, Aesculus D 1, and menthol as active ingredients and zinc oxide and vaseline as ointment base in specific ratio. Ointment of present invention makes it possible to improve microcirculation and cell respiration in tissues, to reduce venous engorgement, to increase immunity, to stimulate regeneration processes.

EFFECT: ointment for treatment of hemorrhoids, dermatitis and rhinitis of improved effect.

1 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: agent, in particular, contains N-(2-ethylsulfonylamino-5-trifluoromethylpyrid-3-yl-cycloxancarboxamide or its salt.

EFFECT: reduced side action and increased therapeutical efficiency.

2 tbl

FIELD: oncological diseases.

SUBSTANCE: invention is designed for use in complex treatment of urinary bladder cancer in case of propagation of tumor to sub-epithelium connective tissue. Method comprises transurethral resection and introduction of immune preparations and furacillin solution. Once transurethral resection completed, three-way Foli catheter is transurethrally introduced to patient, through which mixture of standard furacillin solution with 10·106 ME interferon α-2β is injected from the first postoperative day and over following 3-5 postoperative days bringing summary dose of interferon to 50·106 ME.

EFFECT: prevented traumatism of urinary bladder due to single introduction of catheter and assured continuous action of drugs without development of immune complications.

Up!